Abstract:Abnormalities in B cells play pivotal roles in the pathogenesis of systemic lupus erythematosus (SLE) and lupus nephritis (LN). Breach in central and peripheral tolerance mechanisms generates autoreactive B cells which contribute to the pathogenesis of SLE and LN. Dysregulation of B cell transcription factors, cytokines and B cell-T cell interaction can result in aberrant B cell maturation and autoantibody production. These immunological abnormalities also lead to perturbations in circulating and infiltrating B cells in SLE and LN patients. Conventional and novel immunosuppressive medications confer differential effects on B cells which have important clinical implications. While cyclophosphamide and mycophenolate mofetil (MMF) showed comparable clinical efficacy in active LN, MMF induction was associated with earlier reduction in circulating plasmablasts and plasma cells. Accumulating evidence suggests that MMF maintenance is associated with lower risk of disease relapse than azathioprine, which may be explained by its more potent and selective suppression of B cell proliferation. Novel therapeutic approaches targeting the B cell repertoire include B cell depletion with monoclonal antibodies binding to cell surface markers, inhibition of B cell cytokines, and modulation of costimulatory signals in B cell-T cell interaction. These biologics, despite showing improvements in serological parameters and proteinuria, did not achieve primary endpoints when used as add-on therapy to standard treatments in active LN patients. Other emerging treatments such as calcineurin inhibitors, mammalian target of rapamycin inhibitors and proteasome inhibitors also show distinct inhibitory effects on the B cell repertoire. Advancement in the knowledge on B cell biology has fueled the development of new therapeutic strategies in SLE and LN. Modification in background treatments, study endpoints and selective recruitment of subjects showing aberrant B cells or its signaling pathways when designing future clinical trials may better elucidate the roles of these novel therapies for SLE and LN patients.

The abnormal signaling of the B cell receptor and co-receptors of lupus B cells

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Aberrant B-Cell Activation in Systemic Lupus Erythematosus.

Aberrant CD40-Induced NF-κB Activation in Human Lupus B Lymphocytes

Post-translational Modifications in T Cells in Systemic Erythematosus Lupus

Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus

Toll-like receptor signalling in B cells during systemic lupus erythematosus

B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments

T-cell signaling abnormalities in human systemic lupus erythematosus

The Pathological Role of B Cells in Systemic Lupus Erythematosus: from Basic Research to Clinical

Lymphocytes Change Their Phenotype and Function in Systemic Lupus Erythematosus and Lupus Nephritis

B cell biology and dysfunction in SLE

The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus

B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia

B cell depletion and inhibition in systemic lupus erythematosus

Sphingomyelin Synthase 1 Enhances BCR Signaling to Promote Lupus-Like Autoimmune Response.

B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells

B cells expressing the transcription factor T-bet drive lupus-like autoimmunity

B cell receptor repertoire abnormalities in autoimmune disease

Regulatory B cell and Systemic Lupus Erythematosus

Abnormal Expression of BAFF and Its Receptors in Peripheral Blood and Skin Lesions from Systemic Lupus Erythematosus Patients